Form D · Pharmaceuticals
Alexza Pharmaceuticals Inc.
Mountain View, CA · CIK 0001344413
Offering snapshot reported Feb 24, 2016 · SEC filing
- Reported sold
- $5M Offering amount: $5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 23, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 24, 2016 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| Sep 28, 2015 | Initial | $143,750 | No comparison | 1 | SEC filing |
| Oct 28, 2014 | Initial | $8,000,000 | No comparison | 1 | SEC filing |
| Mar 28, 2014 | Initial | $3,457 | No comparison | 9 | SEC filing |
| May 21, 2013 | Initial | Yet to sell | No comparison | 1 | SEC filing |
| Mar 16, 2012 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
| May 12, 2010 | Initial | $1,012,500 | No comparison | 1 | SEC filing |
| Oct 6, 2009 | Initial | $19,720,309 | No comparison | 30 | SEC filing |
| Aug 27, 2009 | Initial | $0 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-258073
Shares issued in consideration of reduction in outstanding balance of a note dated 5/07/13 by $5,000,000 and forgiveness of accrued and unpaid interest thereunder as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on 2/24/2016
Source: Form D, filed Feb 24, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Hal V Barron | Director |
| J Kevin Buchi | Director |
| Andrew L Busser | Director |
| James V Cassella | Executive |
| Samuel D. Colella | Director |
| Alan D Frazier | Director |
| Edwin S Kamemoto | Executive |
| Thomas B King | Director, Executive |
| Robert A Lippe | Executive |
| Darl Moreland | Executive |
| August J Moretti | Executive |
| Mark K Oki | Executive |
| Deepika R Pakianathan | Director |
| J Leighton Read | Director |
| Gordon Ringold | Director |
| Peter W. Schineller | Executive |
| Michael J Simms | Executive |
| Isaac Stein | Director |
| Joseph L Turner | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2091 Stierlin Court
Mountain View, CA, 94043
Mountain View, CA, 94043